Faculty
Ken Carson.jpg

Kenneth R. Carson, MD, PhD

Assistant Professor
Department of Medicine
Oncology Division
Medical Oncology

Research Interests

  • Health services research:
  •    Cost, quality, and access to cancer care
  •    Drug safety

Contact

  • 314-362-0492 (tel)
  • 314-747-5123 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Campus Box 8056
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Peer-reviewed Publications

  • Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study
    Goyal S, Oak E, Luo J, Cashen AF, Carson K, Fehniger T, DiPersio J, Bartlett NL, Wagner-Johnston ND
    Leuk Lymphoma 2017 Jun 9:1-6; [Epub ahead of print]
  • Analysis of peripheral T-cell lymphoma diagnostic workup in the United States
    Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Collie AM, Gruver AM, Grzywacz BJ, Turakhia S, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM
    Clin Lymphoma Myeloma Leuk 2017 Apr;17(4):193-200
  • A prospective cohort study of patients with peripheral T-cell lymphoma in the United States
    Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM
    Cancer 2017 Apr 1;123(7):1174-1183
  • Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia
    Bennett CL, Berger JR, Sartor O, Carson KR, Hrushesky WJ, Georgantopoulos P, Raisch DW, Norris LB, Armitage JO
    Br J Haematol 2016 Sep 21; [Epub ahead of print]
  • Statins are associated with reduced mortality in multiple myeloma
    Sanfilippo KM, Keller J, Gage BF, Luo S, Wang TF, Moskowitz G, Gumbel J, Blue B, O'Brian K, Carson KR
    J Clin Oncol 2016 Sep 19; [Epub ahead of print]
  • Obesity and the transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based cohort study
    Chang SH, Luo S, Thomas TS, O'Brian KK, Colditz GA, Carlsson NP, Carson KR
    J Natl Cancer Inst 2016 Dec 31;109(5):djw264
  • Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma
    Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, Fronick CC, Fulton RS, Kreisel F, Cashen AF, Carson KR, Berrien-Elliott MM, Bartlett NL, Griffith M, Griffith OL, Fehniger TA
    Blood 2017 Jan 26;129(4):473-483
  • Weight change trends and overall survival in United States veterans with follicular lymphoma treated with chemotherapy
    Xiao DY, Luo S, O'Brian K, Liu W, Carson KR
    Leuk Lymphoma 2017 Apr;58(4):851-858
  • Race-based differences in routine cytogenetic profiles of patients with multiple myeloma
    Blue BJ, Luo S, Sanfilippo KM, Ganti A, Gumbel J, O'Brian K, Carson KR
    Br J Haematol 2017 Jan;176(2):322-324
  • The American Society of Hematology Clinical Research Training Institute is associated with high retention in academic hematology
    King AA, Vesely SK, Elwood J, Basso J, Carson K, Sung L
    Blood 2016 Dec 22;128(25):2881-2885
  • Longitudinal body composition changes in diffuse large B-cell lymphoma survivors: a retrospective cohort study of United States veterans
    Xiao DY, Luo S, O'Brian K, Sanfilippo KM, Ganti A, Riedell P, Lynch RC, Liu W, Kahl BS, Cashen AF, Fehniger TA, Carson KR
    J Natl Cancer Inst 2016 Jul 5;108(11):djw145
  • Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy
    Xiao DY, Luo S, O'Brian K, Ganti A, Riedell P, Sanfilippo KM, Lynch RC, Liu W, Carson KR
    Am J Hematol 2016 Oct;91(10):1002-1007
  • Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data
    Burudpakdee C, Lin HM, Wang W, Seetasith A, Zhu Y, Bonthapally V, Carson KR
    J Med Econ 2016 Oct;19(10):965-72
  • Identifying existing Choosing Wisely recommendations of high relevance and importance to hematology
    Hicks LK, Rajasekhar A, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A, Mueller BU, O'Brien SH, Panepinto JA, Pasquini MC, Sarode R, Wood WA
    Am J Hematol 2016 Aug;91(8):787-92
  • Toward a modern science of obesity at Washington University: How we do it and what is the payoff?
    Colditz GA, Gehlert S, Bowen DJ, Carson K, Hovmand PS, Lee JA, Moley KH
    Cancer Prev Res (Phila) 2016 Jul;9(7):503-8
  • Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma
    Sanfilippo KM, Wang TF, Gage BF, Luo S, Riedell P, Carson KR
    Thromb Res 2016 Jul;143:86-90
  • Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria
    Rashidi A, Oak E, Carson KR, Wagner-Johnston ND, Kreisel F, Bartlett NL
    Leuk Lymphoma 2016 May;57(5):1191-1193
  • Short- and long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy
    O'Brian K, Luo S, Ganti A, Riedell P, Lynch RC, Roop R, Sanfilippo KM, Liu W, Colditz GA, Carson KR
    Leuk Lymphoma 2016 Feb;57(2):313-9
  • A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial
    Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B, Pinter-Brown LC, Smith SM, Shustov AR, Savage KJ, M Vose J
    Br J Haematol 2016 Feb;172(4):535-44
  • Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update
    Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO
    J Clin Oncol 2015 Oct 1;33(28):3199-212
  • Risk-adapted strategies for the treatment of Hodgkin lymphoma
    Keller J, Carson KR
    Expert Opin Drug Saf 2015 Oct;14(10):1519-30
  • High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma
    Wildes TM, Finney JD, Fiala M, Gao F, Vij R, Stockerl-Goldstein K, Carson KR, Mikhael J, Colditz G
    Bone Marrow Transplant 2015 Aug;50(8):1075-82
  • Association between metformin use and transformation of monoclonal gammopathy of undetermined significance to multiple myeloma in U.S. veterans with diabetes mellitus: a population-based cohort study
    Chang SH, Luo S, O'Brian KK, Thomas TS, Colditz GA, Carlsson NP, Carson KR
    Lancet Haematol 2015 Jan 1;2(1):e30-e36
  • Variability in the practice of fertility preservation for patients with cancer
    Reynolds KA, Grindler NM, Rhee JS, Cooper AR, Ratts VS, Carson KR, Jungheim ES
    PLoS One 2015 May 26;10(5):e0127335
  • Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma
    Carson KR, Riedell P, Lynch R, Nabhan C, Wildes TM, Liu W, Ganti A, Roop R, Sanfilippo KM, O'Brian K, Liu J, Bartlett NL, Cashen A, Wagner-Johnston N, Fehniger TA, Colditz GA
    J Geriatr Oncol 2015 May;6(3):211-8
  • Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data
    Sanfilippo KM, Wang TF, Gage BF, Liu W, Carson KR
    Thromb Res 2015 Apr;135(4):616-20
  • Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma
    Sanfilippo KM, Gage B, Luo S, Weilbaecher K, Tomasson M, Vij R, Colditz G, Carson K
    Leuk Lymphoma 2015 Mar;56(3):615-21
  • Expression of helper T cell master regulators in inflammatory dermatoses and primary cutaneous T-cell lymphomas: Diagnostic implications
    Hsi AC, Lee SJ, Rosman IS, Carson KR, Kelley A, Viele V, Pang X, Musiek A, Schaffer A
    J Am Acad Dermatol 2015 Jan;72(1):159-67
  • Reply to magnetic resonance imaging-based diagnosis of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma after therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab
    Bennett CL, Newsome SD, Sartor O, Carson KR
    Cancer 2014 Dec 15;120(24):4006-7
  • Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?
    Hudson MA, Luo S, Chrusciel T, Yan Y, Grubb RL 3rd, Carson K, Scherrer JF
    Urol Oncol 2014 Jan;32(1):34e9-34e18
  • Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
    Ganti A, Liu W, Luo S, Sanfilippo KM, Roop R, Lynch R, Riedell P, O'Brian K, Colditz GA, Carson KR
    Br J Haematol 2014 Dec;167(5):699-702
  • Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project
    Carson KR, Newsome SD, Kim EJ, Wagner-Johnston ND, von Geldern G, Moskowitz CH, Moskowitz AJ, Rook AH, Jalan P, Loren AW, Landsburg D, Coyne T, Tsai D, Raisch DW, Norris LB, Bookstaver PB, Sartor O, Bennett CL
    Cancer 2014 Aug 15;120(16):2464-71
  • The skinny on obesity and plasma cell myeloma: a review of the literature
    Carson KR, Bates ML, Tomasson MH
    Bone Marrow Transplant 2014 Aug;49(8):1009-15
  • A drug safety evaluation of rituximab and risk of hepatitis B
    Riedell P, Carson KR
    Expert Opin Drug Saf 2014 Jul;13(7):977-87
  • High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis
    May J, Carson KR, Butler S, Liu W, Bartlett NL, Wagner-Johnston ND
    Leuk Lymphoma 2014 Jun;55(6):1345-9
  • Surveillance imaging for lymphoma: pros and cons
    Lynch RC, Zelenetz AD, Armitage JO, Carson KR
    Am Soc Clin Oncol Educ Book 2014:e388-95
  • Five hematologic tests and treatments to question
    Hicks LK, Bering H, Carson KR, Haynes AE, Kleinerman J, Kukreti V, Ma A, Mueller BU, O'Brien SH, Panepinto JA, Pasquini MC, Rajasekhar A, Sarode R, Wood WA
    Hematology Am Soc Hematol Educ Program 2014 Dec 5;2014(1):599-603
  • The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide
    Wang TF, Ahluwalia R, Fiala MA, Trinkaus KM, Cox DP, Jaenicke M, Moliske CC, Carson KR, Wildes TM, Tomasson MH, Stockerl-Goldstein KE, Vij R
    Leuk Lymphoma 2014 Feb;55(2):337-41
  • A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma
    Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI
    Ann Oncol 2013 Dec;24(12):3076-81
  • The ASH Choosing Wisely(R) campaign: five hematologic tests and treatments to question
    Hicks LK, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A, Mueller BU, O'Brien SH, Pasquini M, Sarode R, Solberg L Jr, Haynes AE, Crowther MA
    Blood 2013 Dec 5;122(24):3879-83
  • Influence of body mass index on survival in veterans with multiple myeloma
    Beason TS, Chang SH, Sanfilippo KM, Luo S, Colditz GA, Vij R, Tomasson MH, DiPersio JF, Stockerl-Goldstein K, Ganti A, Wildes T, Carson KR
    Oncologist 2013;18(10):1074-9
  • Geriatric assessment is associated with completion of chemotherapy, toxicity and survival in older adults with cancer
    Wildes TM, Ruwe AP, Fournier C, Gao F, Carson KR, Piccirillo JF, Tan B, Colditz GA
    J Geriatr Oncol 2013 Jul;4(3):227-234
  • The 2011-2016 Transdisciplinary Research on Energetics and Cancer (TREC) initiative: rationale and design
    Patterson RE, Colditz GA, Hu FB, Schmitz KH, Ahima RS, Brownson RC, Carson KR, Chavarro JE, Chodosh LA, Gehlert S, Gill J, Glanz K, Haire-Joshu D, Herbst KL, Hoehner CM, Hovmand PS, Irwin ML, Jacobs LA, James AS, Jones LW, Kerr J, Kibel AS, King IB, Ligibel JA, Meyerhardt JA, Natarajan L, Neuhouser ML, Olefsky JM, Proctor EK, Redline S, Rock CL, Rosner B, Sarwer DB, Schwartz JS, Sears DD, Sesso HD, Stampfer MJ, Subramanian SV, Taveras EM, Tchou J, Thompson B, Troxel AB, Wessling-Resnick M, Wolin KY, Thornquist MD
    Cancer Causes Control 2013 Apr;24(4):695-704
  • Obesity and reproductive function
    Jungheim ES, Travieso JL, Carson KR, Moley KH
    Obstet Gynecol Clin North Am 2012 Dec;39(4):479-93
  • Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma
    Carson KR, Bartlett NL, McDonald JR, Luo S, Zeringue A, Liu J, Fu Q, Chang SH, Colditz GA
    J Clin Oncol 2012 Sep 10;30(26):3217-22
  • Economic evaluation of plerixafor for stem cell mobilization
    Kymes SM, Pusic I, Lambert DL, Gregory M, Carson KR, DiPersio JF
    Am J Manag Care 2012 Jan;18(1):33-41
  • A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
    Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL
    Blood 2011 Nov 10;118(19):5119-25
  • Technology assessment: report on the evidence regarding off-label indications for targeted therapies used in cancer treatment
    Abernethy AP, Coeytaux RR, Carson K, et al.
    Rockville, MD: Agency for Healthcare Quality and Research, U.S. Department of Health and Human Services, 2009
  • Obesity and cancer
    Wolin KY, Carson K, Colditz GA
    Oncologist 2010;15(6):556-65
  • Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib
    Carson KR, Beckwith LG, Mehta J
    Blood 2010 Jan 28;115(4):915
  • Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project
    Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL
    Lancet Oncol 2009 Aug;10(8):816-24
  • Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
    Richey EA, Lyons EA, Nebeker JR, Shankaran V, McKoy JM, Luu TH, Nonzee N, Trifilio S, Sartor O, Benson AB 3rd, Carson KR, Edwards BJ, Gilchrist-Scott D, Kuzel TM, Raisch DW, Tallman MS, West DP, Hirschfeld S, Grillo-Lopez AJ, Bennett CL
    J Clin Oncol 2009 Sep 10;27(26):4398-405
  • Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
    Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL
    Blood 2009 May 14;113(20):4834-40
  • Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating
    Carson KR, Bennett CL
    Leuk Lymphoma 2009 Mar;50(3):323-4
  • Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw
    Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C, Marx R, Ruggiero S, Dimopoulos M, Raisch DW, Singhal S, Carson K, Obadina E, Trifilio S, West D, Mehta J, Bennett CL
    Lancet Oncol 2008 Dec;9(12):1166-72
  • Clinical characteristics of erythropoietin-associated pure red cell aplasia
    Carson KR, Evens AM, Bennett CL, Luminari S
    Best Pract Res Clin Haematol 2005;18(3):467-72
  • Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetIn: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project
    Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM, Locatelli F, Belknap SM, McKoy JM, Lyons EA, Kim B, Sharma R, Costello S, Toffelmire EB, Wells GA, Messner HA, Yarnold PR, Trifilio SM, Raisch DW, Kuzel TM, Nissenson A, Lim LC, Tallman MS, Casadevall N
    Blood 2005 Nov 15;106(10):3343-7
  • The Research on Adverse Drug Events and Reports (RADAR) project
    Bennett CL, Nebeker JR, Lyons EA, Samore MH, Feldman MD, McKoy JM, Carson KR, Belknap SM, Trifilio SM, Schumock GT, Yarnold PR, Davidson CJ, Evens AM, Kuzel TM, Parada JP, Cournoyer D, West DP, Sartor O, Tallman MS, Raisch DW
    JAMA 2005 May 4;293(17):2131-40
  • Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs
    McKoy JM, Lyons EA, Obadina E, Carson K, Pickard AS, Schellhammer P, McLeod D, Boyd CE, McWilliams N, Sartor O, Schumock GT, McCaffery K, Bennett CL
    J Clin Oncol 2005 Dec 1;23(34):8894-905
  • Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans
    Wolf MS, Fitzner KA, Powell EF, McCaffrey KR, Pickard AS, McKoy JM, Lindenberg J, Schumock GT, Carson KR, Ferreira MR, Dolan NC, Bennett CL
    J Clin Oncol 2005 Dec 1;23(34):8877-83